Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -1082.20% is 198% below its 5-year average of -363.52%, near the low end of its 5-year range (-1082.20%–-35.35%).
As of the fiscal period ended Wednesday, December 31, 2025. 65.81% below its 12-month average of -652.69%.
Reported quarterly return on assets; no daily interpolation. Q4 FY2025 (2025-12-31): -312.06%.
RETURN ON ASSETS (ROA)
-1082.20%
RETURN ON ASSETS (ROA) AVG TTM
-652.69%
RETURN ON ASSETS (ROA) AVG 3Y
-445.69%
RETURN ON ASSETS (ROA) AVG 5Y
-363.52%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-65.81%
CURRENT VS 3Y AVG
-142.82%
CURRENT VS 5Y AVG
-197.70%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.18%
median of 678 covered companies
CURRENT VS SECTOR MEDIAN
-3485.22%
vs the sector median at left
NeuroSense Therapeutics Ltd.
Market Cap
$7.02M
Return on Assets (ROA)
-1082.20%
TTM Avg
-652.69%
3Y Avg
-445.69%
5Y Avg
-363.52%
Market Cap
$6.98M
Return on Assets (ROA)
-106.57%
TTM Avg
-92.47%
3Y Avg
-315.20%
5Y Avg
-267.86%
Market Cap
$7.13M
Return on Assets (ROA)
-283.63%
TTM Avg
-124.17%
3Y Avg
-74.25%
5Y Avg
-35.74%
Market Cap
$7.26M
Return on Assets (ROA)
-206.32%
TTM Avg
-53.14%
3Y Avg
-33.03%
5Y Avg
-33.03%
Market Cap
$7.28M
Return on Assets (ROA)
-95.26%
TTM Avg
-176.86%
3Y Avg
-120.19%
5Y Avg
-105.02%
Market Cap
$7.31M
Return on Assets (ROA)
-414.54%
TTM Avg
-226.50%
3Y Avg
-135.75%
5Y Avg
-126.75%
Market Cap
$6.66M
Return on Assets (ROA)
-50.98%
TTM Avg
-191.11%
3Y Avg
-206.10%
5Y Avg
-240.87%
Market Cap
$6.62M
Return on Assets (ROA)
-97.60%
TTM Avg
-274.34%
3Y Avg
-160.93%
5Y Avg
-165.76%
Market Cap
$7.43M
Return on Assets (ROA)
-151.57%
TTM Avg
-141.88%
3Y Avg
-132.44%
5Y Avg
-101.65%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NeuroSense Therapeutics Ltd. (NRSN) | $7.02M | -1082.20% | -652.69% | -445.69% | -363.52% |
| Mangoceuticals, Inc. (MGRX)vs › | $6.98M | -106.57% | -92.47% | -315.20% | -267.86% |
| Co-Diagnostics, Inc. (CODX)vs › | $7.13M | -283.63% | -124.17% | -74.25% | -35.74% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.26M | -206.32% | -53.14% | -33.03% | -33.03% |
| KALA BIO, Inc. (KALA)vs › | $7.28M | -95.26% | -176.86% | -120.19% | -105.02% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | -414.54% | -226.50% | -135.75% | -126.75% |
| Aclarion, Inc. (ACON)vs › | $6.66M | -50.98% | -191.11% | -206.10% | -240.87% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.62M | -97.60% | -274.34% | -160.93% | -165.76% |
| Longeveron Inc. (LGVN)vs › | $7.43M | -151.57% | -141.88% | -132.44% | -101.65% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.49M | -71.23% | -61.08% | -51.04% | -61.11% |
ROA
-1082.2%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -1082.20% |
| 2024-12-31 | -223.17% |
| 2023-12-31 | -317.33% |
| 2022-12-31 | -160.05% |
| 2021-12-31 | -35.35% |
| 2020-12-31 | -363.03% |
| 2019-12-31 | -128.48% |
